Terms: = Prostate cancer AND ERG, P11308, 2078 AND Clinical Outcome
40 results:
1. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
[TBL] [Abstract] [Full Text] [Related]
2. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
[TBL] [Abstract] [Full Text] [Related]
3. The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal prostate cancer.
Gamallat Y; Bakker A; Khosh Kish E; Choudhry M; Walker S; Aldakheel S; Seyedi S; Huang KC; Ghosh S; Gotto G; Bismar TA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362115
[TBL] [Abstract] [Full Text] [Related]
4. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
5. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
6. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract] [Full Text] [Related]
7. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract] [Full Text] [Related]
8. Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
Borkowetz A; Froehner M; Rauner M; Conrad S; Erdmann K; Mayr T; Datta K; Hofbauer LC; Baretton GB; Wirth M; Fuessel S; Toma M; Muders MH
Int J Cancer; 2020 May; 146(9):2619-2627. PubMed ID: 31509606
[TBL] [Abstract] [Full Text] [Related]
9. clinical utility of assessing PTEN and erg protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract] [Full Text] [Related]
10. High throughput differential identification of TMPRSS2-erg fusion genes in prostate cancer patient urine.
Lee H; Lee D; Park JH; Song SH; Jeong IG; Kim CS; Searson PC; Lee KH
Biomaterials; 2017 Aug; 135():23-29. PubMed ID: 28478327
[TBL] [Abstract] [Full Text] [Related]
11. High alpha-methylacyl-CoA racemase (AMACR) is associated with erg expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract] [Full Text] [Related]
12. SPINK1 Overexpression in Localized prostate cancer: a Rare Event Inversely Associated with erg Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract] [Full Text] [Related]
13. IL-6 Overexpression in erg-Positive prostate cancer Is Mediated by Prostaglandin Receptor EP2.
Merz C; von Mässenhausen A; Queisser A; Vogel W; Andrén O; Kirfel J; Duensing S; Perner S; Nowak M
Am J Pathol; 2016 Apr; 186(4):974-84. PubMed ID: 27012192
[TBL] [Abstract] [Full Text] [Related]
14. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
Liu W
Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
[TBL] [Abstract] [Full Text] [Related]
15. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.
Bakkar A; Alshalalfa M; Petersen LF; Abou-Ouf H; Al-Mami A; Hegazy SA; Feng F; Alhajj R; Bijian K; Alaoui-Jamali MA; Bismar TA
Mol Biol Rep; 2016 Apr; 43(4):229-40. PubMed ID: 26907180
[TBL] [Abstract] [Full Text] [Related]
16. NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
[TBL] [Abstract] [Full Text] [Related]
17. Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.
Kluth M; Ahrary R; Hube-Magg C; Ahmed M; Volta H; Schwemin C; Steurer S; Wittmer C; Wilczak W; Burandt E; Krech T; Adam M; Michl U; Heinzer H; Salomon G; Graefen M; Koop C; Minner S; Simon R; Sauter G; Schlomm T
Oncotarget; 2015 Sep; 6(29):27966-79. PubMed ID: 26293672
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of erg and SPINK1 by Immunohistochemical Staining and Clinicopathological outcomes in a Multi-Institutional Radical prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract] [Full Text] [Related]
19. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract] [Full Text] [Related]
20. TMPRSS2-erg gene fusion in prostate cancer.
Burdova A; Bouchal J; Tavandzis S; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):502-10. PubMed ID: 25485532
[TBL] [Abstract] [Full Text] [Related]
[Next]
